Skip to main content

Table 2 Response assessment according to line and type of targeted therapy

From: Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma

Line of targeted therapy

PFS in months (range)

 

All

Sun

Sor

Eve

Tem

Other

1st

2.4

PR

      
 

(1-4.6)

SD

      
  

PD

35

28

7

   

2nd

3.2

PR

      
 

(1-16.6)

SD

10

1

4

3

2

 
  

PD

15

2

8

4

1

 

3rd

1.9

PR

1

   

1

 
 

(1-15)

SD

4

 

1

1

 

2

  

PD

9

  

6

1

2

4th

2.6

PR

      
 

(1-9)

SD

4

  

1

 

3

  

PD

3

 

1

 

1

1

  1. Abbreviations:PFS - progression free survival; Sun - sunitinib; Sor - sorafenib; Eve - everolimus; Tem - temsirolimus; PR - partial response; SD - stable disease; PD - progressive disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us